Intec Pharma Ltd Logo

Intec Pharma Ltd

NTEC

(1.2)
Stock Price

9,63 USD

-67.61% ROA

-108.39% ROE

-0.67x PER

Market Cap.

0,00 USD

0% DER

0% Yield

0% NPM

Intec Pharma Ltd Stock Analysis

Intec Pharma Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Intec Pharma Ltd Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.65x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (44%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-108.39%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-67.61%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Intec Pharma Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Intec Pharma Ltd Technical Stock Analysis
# Analysis Recommendation

Intec Pharma Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Intec Pharma Ltd Revenue
Year Revenue Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Intec Pharma Ltd Research and Development Expenses
Year Research and Development Expenses Growth
2013 2.589.232
2014 3.409.000 24.05%
2015 4.790.632 28.84%
2016 10.749.000 55.43%
2017 24.295.000 55.76%
2018 35.402.000 31.37%
2019 26.659.000 -32.8%
2020 6.740.000 -295.53%
2021 8.628.000 21.88%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Intec Pharma Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 2.743.431
2014 2.589.000 -5.96%
2015 2.754.338 6%
2016 3.072.000 10.34%
2017 5.117.000 39.96%
2018 7.926.000 35.44%
2019 8.287.000 4.36%
2020 7.089.000 -16.9%
2021 8.084.000 12.31%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Intec Pharma Ltd EBITDA
Year EBITDA Growth
2013 -4.631.443
2014 -5.085.000 8.92%
2015 -6.385.290 20.36%
2016 -12.645.000 49.5%
2017 -28.218.000 55.19%
2018 -42.558.000 33.7%
2019 -46.092.000 7.67%
2020 -12.801.000 -260.07%
2021 -14.608.000 12.37%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Intec Pharma Ltd Gross Profit
Year Gross Profit Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Intec Pharma Ltd Net Profit
Year Net Profit Growth
2013 -5.280.689
2014 -5.693.000 7.24%
2015 -7.143.040 20.3%
2016 -13.362.000 46.54%
2017 -29.093.000 54.07%
2018 -43.543.000 33.19%
2019 -47.599.000 8.52%
2020 -14.128.000 -236.91%
2021 -16.916.000 16.48%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Intec Pharma Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -98
2014 -94 -3.19%
2015 -73 -28.77%
2016 -93 21.51%
2017 -132 29.01%
2018 -112 -18.02%
2019 -113 0.89%
2020 -14 -700%
2021 -15 6.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Intec Pharma Ltd Free Cashflow
Year Free Cashflow Growth
2013 -5.052.118
2014 -4.827.000 -4.66%
2015 -9.273.605 47.95%
2016 -12.487.000 25.73%
2017 -27.133.000 53.98%
2018 -48.675.000 44.26%
2019 -32.831.000 -48.26%
2020 -11.533.000 -184.67%
2021 -4.312.000 -167.46%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Intec Pharma Ltd Operating Cashflow
Year Operating Cashflow Growth
2013 -3.508.399
2014 -4.751.000 26.15%
2015 -7.889.007 39.78%
2016 -12.005.000 34.29%
2017 -22.132.000 45.76%
2018 -39.076.000 43.36%
2019 -29.045.000 -34.54%
2020 -11.511.000 -152.32%
2021 -4.311.000 -167.01%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Intec Pharma Ltd Capital Expenditure
Year Capital Expenditure Growth
2013 1.543.719
2014 76.000 -1931.21%
2015 1.384.598 94.51%
2016 482.000 -187.26%
2017 5.001.000 90.36%
2018 9.599.000 47.9%
2019 3.786.000 -153.54%
2020 22.000 -17109.09%
2021 1.000 -2100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Intec Pharma Ltd Equity
Year Equity Growth
2014 9.481.000
2015 35.515.132 73.3%
2016 22.704.000 -56.43%
2017 58.802.000 61.39%
2018 53.545.000 -9.82%
2019 11.535.000 -364.2%
2020 14.533.000 20.63%
2021 11.344.000 -28.11%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Intec Pharma Ltd Assets
Year Assets Growth
2014 12.502.000
2015 37.155.131 66.35%
2016 24.721.000 -50.3%
2017 64.549.000 61.7%
2018 61.510.000 -4.94%
2019 21.280.000 -189.05%
2020 20.896.000 -1.84%
2021 17.430.000 -19.89%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Intec Pharma Ltd Liabilities
Year Liabilities Growth
2014 3.021.000
2015 1.639.999 -84.21%
2016 2.017.000 18.69%
2017 5.747.000 64.9%
2018 7.965.000 27.85%
2019 9.745.000 18.27%
2020 6.363.000 -53.15%
2021 6.086.000 -4.55%

Intec Pharma Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-14.3
Price to Earning Ratio
-0.67x
Price To Sales Ratio
0x
POCF Ratio
-0.83
PFCF Ratio
0
Price to Book Ratio
0.65
EV to Sales
0
EV Over EBITDA
1.07
EV to Operating CashFlow
1.19
EV to FreeCashFlow
1.19
Earnings Yield
-1.48
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
68.79
Graham NetNet
8.47

Income Statement Metrics

Net Income per Share
-14.3
Income Quality
0.81
ROE
-1.08
Return On Assets
-0.68
Return On Capital Employed
-0.89
Net Income per EBT
1.01
EBT Per Ebit
1.01
Ebit per Revenue
0
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-11.65
Free CashFlow per Share
-11.67
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
-0.02
Return on Invested Capital
-0.96
Return on Tangible Assets
-0.68
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0.02

Balance Sheet

Cash per Share
14,85
Book Value per Share
14,71
Tangible Book Value per Share
14.71
Shareholders Equity per Share
14.71
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
1.07
Current Ratio
2.81
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Intec Pharma Ltd Dividends
Year Dividends Growth

Intec Pharma Ltd Profile

About Intec Pharma Ltd

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.

CEO
Mr. Jeffrey Meckler
Employee
36
Address
12 Hartom Street, Har Hotzvim
JERUSALEM, 9777512

Intec Pharma Ltd Executives & BODs

Intec Pharma Ltd Executives & BODs
# Name Age

Intec Pharma Ltd Competitors